CG Oncology Inc CGON
News
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
CG Oncology to Present at Upcoming Investor Conferences in September
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm

